Clinical trial
Metabolic Effects of Antipsychotics in Children
NCT00205699 · Washington University School of Medicine, Other · Completed
Key facts
| NCT number | NCT00205699 |
|---|---|
| Title | Metabolic Effects of Antipsychotics in Children |
| Official title | Metabolic Effects of Antipsychotics in Children |
| Acronym | MEAC |
| Lead sponsor | Washington University School of Medicine, Other |
| Collaborators | National Institute of Mental Health (NIMH) NIH |
| Status | Completed |
| Phase | Phase 4 |
| Study type | Interventional |
| Conditions | Aggression, Attention Deficit-Hyperactivity, Oppositional Defiant Disorder, Pervasive Development Disorders, Bipolar Disorder |
| Intervention type | Drug |
| Interventions | risperidone, olanzapine, aripiprazole |
| Enrollment | 144 |
| Start date | Apr 1, 2006 |
| Primary completion | Mar 1, 2011 |
| Completion | Jul 1, 2011 |
| First posted | Sep 20, 2005 |
| Last update posted | Jun 15, 2018 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: